With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.
5317-33-9, A solution of diisopropyl azodicarboxylate (12.1 ml) in methylene chloride (50 ml) was added dropwise during 30 minutes to a stirred mixture of 4-chloro-3-cyano-7-hydroxy- 6-methoxyquinoline (12 g), 1-(3-hydroxypropyl)-4-methylpiperazine (9.7 g), triphenylphosphine (16.1 g) and methylene chloride (200 ml) that had been cooled to [5C.] The resultant mixture was allowed to warm to ambient temperature and was then stirred for 1 hour. Further portions of diisopropyl azodicarboxylate (1. [2 ML)] and triphenylphosphine (1.6 g) were added and the mixture was stirred at ambient temperature for a further 1 hour. The mixture was poured into water and the organic layer was separated, washed with a saturated brine solution, dried over magnesium sulphate and evaporated. The material so obtained was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained the required starting material as a solid (14.5 g); NMR Spectrum : [(DMSOD6)] [1.] 95 (m, 2H), 2.13 (s, 3H), 2.24-2. 5 [(M, L OH),] 4.0 (s, 3H), 4.25 (t, 2H), 7.43 (s, [1H),] 7.51 (s, [1H),] 8.95 (s, [1H)] ; Mass Spectrum : M+H+ 375 and 377.
As the paragraph descriping shows that 5317-33-9 is playing an increasingly important role.
Reference：
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2004/5284; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics